Synmosa Biopharma
Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches, develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand in Taiwan. The company offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company also provides its products in various forms, suc… Read more
Synmosa Biopharma (4114) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.001x
Based on the latest financial reports, Synmosa Biopharma (4114) has a cash flow conversion efficiency ratio of 0.001x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$7.02 Million) by net assets (NT$9.95 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Synmosa Biopharma - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Synmosa Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Synmosa Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Synmosa Biopharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aditya Birla Fashion and Retail Limited
NSE:ABFRL
|
-0.015x |
|
Suzhou HYC Technology Co Ltd
SHG:688001
|
0.057x |
|
BLUE LABEL
MU:5TP
|
N/A |
|
Clean Science and Technology Limited
NSE:CLEAN
|
0.015x |
|
JAPAN AVIATION EL.
F:8N9
|
N/A |
|
Personalis Inc
NASDAQ:PSNL
|
-0.127x |
|
Digital Turbine Inc
NASDAQ:APPS
|
0.073x |
|
Vox Royalty Corp. Common Stock
NASDAQ:VOXR
|
0.017x |
Annual Cash Flow Conversion Efficiency for Synmosa Biopharma (2015–2024)
The table below shows the annual cash flow conversion efficiency of Synmosa Biopharma from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$8.40 Billion | NT$780.62 Million | 0.093x | +47.08% |
| 2023-12-31 | NT$8.10 Billion | NT$511.93 Million | 0.063x | -33.33% |
| 2022-12-31 | NT$6.65 Billion | NT$630.25 Million | 0.095x | +30.05% |
| 2021-12-31 | NT$6.10 Billion | NT$444.29 Million | 0.073x | +70.61% |
| 2020-12-31 | NT$5.95 Billion | NT$254.40 Million | 0.043x | +558.15% |
| 2019-12-31 | NT$4.81 Billion | NT$-44.88 Million | -0.009x | -361.48% |
| 2018-12-31 | NT$4.49 Billion | NT$16.00 Million | 0.004x | +372.28% |
| 2017-12-31 | NT$3.97 Billion | NT$-5.19 Million | -0.001x | -102.41% |
| 2016-12-31 | NT$4.35 Billion | NT$236.48 Million | 0.054x | +593.84% |
| 2015-12-31 | NT$3.01 Billion | NT$23.60 Million | 0.008x | -- |